Newark, NJ (April 14, 2015) – Endomedix, Inc. announced today that NIH has selected Endomedix to showcase its technology at the upcoming Biotechnology Industry Organization (BIO) annual meeting in Philadelphia, June 15-18, 2015. The National Institute for Neurological Disorders and Stroke is currently funding the Endomedix program to develop a surgical hemostat indicated for use in intracranial surgery through a multi-year Phase II SBIR grant.
Through the SBIR program, NIH funds promising technologies and assists its grantees further on the path to commercialization. NIH is partnering with BIO to provide select grantees with premium visibility at the BIO International Convention, providing these firms with access to business development executives and investors from around the world.
Endomedix’s exhibit will be located in a special 5000 square foot Innovation Zone dedicated to showcasing 35 NIH and 35 National Science Foundation grantees. NIH will issue Endomedix an administrative supplement award to offset expenses associated with its participation in the BIO Conference Innovation Zone. In addition to the exhibit, Endomedix will be included in BIO’s special on-site partnering and networking programs, as well as a series of promotions and announcements.
“We are both honored and enthusiastic about the opportunity to present our technology and progress on a truly global stage”, stated Endomedix CEO, Richard Russo. “The timing of this event is optimal, as our program has just reached a major milestone and we are preparing to raise investment funds for the next phase of our program”.
As the world’s largest biotech conference and exhibition, the annual BIO meeting attracts 15,000 biotech leaders from 65 countries and covers the wide spectrum of life science innovations. The key elements of the conference are education, networking, the BIO exhibition featuring 1,800 companies, and BIO one-on-One PartneringTM, which facilitates more than 29,000 strategic partnering meetings during the three-day event.
Endomedix is a medical device firm located in the Enterprise Development Center incubator at NJIT. The firm has developed a patented technology with potential use in a number of medical product applications. The firm’s first device will be a surgical hemostat intended for use in brain surgery, for which the device will have unique important features that promise to both significantly reduce costs and improve clinical outcomes in these surgeries.
For additional information, contact Richard Russo at rrusso@endomedix.com.